Intensity Therapeutics Chosen for Oral Presentation at 2024 Connective Tissue Oncology Society Meeting

In a recent announcement from Shelton, Connecticut, Intensity Therapeutics, Inc. (Nasdaq: INTS), a company at the forefront of clinical biotechnology, revealed that its Phase 3 trial will be featured in an oral presentation at the 2024 Connective Tissue Oncology Society (CTOS) conference on November 16, 2024. Dr. Christian F. Meyer, MD, Ph.D., will present the completed results from Phase 2 and discuss the design and key criteria of the INVINCIBLE-3 Phase 3 randomized trial for soft tissue sarcoma. The CTOS event is scheduled to take place from November 13 to 16, 2024, at the Grand Hyatt in San Diego.

The presentation details are as follows:
Session 11, titled "Trials in Progress/Late Breaking Trials," will feature Paper 78, which discusses a multicenter, randomized Phase 3 study comparing the intratumoral injection of INT230-6 (a combination of SHAO, vinblastine, and cisplatin) with standard care therapy in patients with metastatic soft tissue sarcomas. This presentation is scheduled for Saturday, November 16, 2024, at 9:00 AM PST in the Harbor Ballroom. The lead author is Dr. Albiruni Abdul Razak from the Toronto Sarcoma Program at Princess Margaret Cancer Center, with Dr. Christian F. Meyer from Johns Hopkins University delivering the presentation.

Intensity Therapeutics focuses on creating innovative cancer treatments through the development of INT230-6. This drug formulation utilizes engineered chemistry to saturate and penetrate the dense, high-fat environment of tumors, resulting in tumor cell death and the induction of an adaptive immune response. This unique approach has the potential to transform cancer treatment, possibly converting fatal cancers into manageable chronic conditions.

The company has completed two significant clinical studies involving INT230-6, enrolling over 200 patients. These include a Phase 1/2 dose escalation trial (NCT03058289) and a Phase 2 randomized control trial in breast cancer, known as the INVINCIBLE-2 study (NCT04781725). Intensity Therapeutics has also initiated a Phase 3 trial for soft tissue sarcoma, the INVINCIBLE-3 study (NCT06263231), to evaluate INT230-6 as a second or third-line treatment compared to standard care, with overall survival as the primary endpoint.

Furthermore, Intensity Therapeutics is engaged in a Phase 2 study in partnership with The Swiss Group for Clinical Cancer Research. This is part of a broader Phase 2/3 program assessing INT230-6 followed by standard care, compared to standard care alone, in patients with presurgical triple-negative breast cancer. The Phase 2 segment of this program is documented under the INVINCIBLE-4 study (NCT06358573).

The Connective Tissue Oncology Society (CTOS), established in 1995 and incorporated in 1997, is an international organization comprising physicians and scientists dedicated to the study and treatment of connective tissue tumors, such as soft tissue sarcomas. These tumors, which can develop in muscles, fat, blood vessels, and nerves, are rare but serious. CTOS aims to improve patient care and advance knowledge in the biology of these tumors through both basic and clinical research.